Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy
复制标题
DOI：
10.1038/leu.2015.108
复制
发表时间：
2015-04
期刊：
影响因子：
11.4
通讯作者：
N. Lachmann;K. Czarnecki;Sebastian Brennig;R. Phaltane;R. Phaltane;M. Heise;Niels Heinz;Niels Heinz-Niels
中科院分区：
文献类型：
--
作者：
N. Lachmann;K. Czarnecki;Sebastian Brennig;R. Phaltane;R. Phaltane;M. Heise;Niels Heinz;Niels Heinz-Niels
3 Luatti S，Castagnetti F，Marzocchi G，Baldazzi C，Gugliotta G，Iacobucci I et al.费城阳性克隆中的其他染色体异常：对一线伊马替尼治疗的不良预后影响：GMEMA工作组对CML分析。血液2012; 120：761-767。4科尔特斯JE，Talpaz M，Giles F，奥布莱恩S，Rios MB，Shan J等.甲磺酸伊马替尼治疗慢性粒细胞白血病患者细胞遗传学克隆演变的预后意义.血液2003; 101：3794-3800。[5]杨文军，李晓梅，李晓梅.慢性粒细胞白血病的细胞遗传学和分子遗传学演变。血液学学报2002; 107：76-94. 6 Mu Q，Ma Q，Wang Y，Chen Z，Tong X，Chen FF，et al. Cytogenetic profile of 1，863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from Chinese population. Ann Hematol 2012; 91：1065-1072. 7 Burke BA，卡罗尔M. BCR-ABL：慢性粒细胞白血病DNA突变的多面启动子白血病2010; 24：1105-1112。8海尔曼河如何治疗CML急变期。Blood 2012; 120：737-747. 9 Fioretos T，Johansson B.慢性髓系锚白血病。In：Heim S，Mitelman F（eds）.癌症细胞遗传学Wiley-Blackwell：Hoboken，NJ，USA，2009，pp 179-207. 10 Baccarani M，Deininger MW，Rosti G，Hochhaus A，Soverini S，Apperley JF等. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013血液2013; 122：872-884。11 Vardiman JW，梅洛JV，Baccarani M，Thiele J.慢性粒细胞白血病，BCR-ABL 1阳性。In：Swerdlow SH，Campo E，Harris NL，Jaffe ES，Pileri SA，Stein H et al.（eds）。WHO Classifiction of Tumours of Haematopoietic and Aphyoid Tissues.IARC：里昂，2008，pp 32-37. 12 Verma D，Kantarjian H，Shan J，奥布莱恩S，Estrov Z，Garcia-Manero G等.第二代酪氨酸激酶抑制剂治疗慢性髓性白血病患者克隆进化的生存结局。Cancer 2010; 116：2673-2681. 13 Lippert E，Etienne G，Mozziconacci MJ，Laibe S，热尔韦C，Girault S等.费城阳性细胞中Y染色体的缺失预测慢性髓性白血病患者对甲磺酸伊马替尼治疗的不良反应。Haematologica 2010; 95：1604-1607.
3 Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012; 120: 761-767. 4 Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101: 3794-3800. 5 Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76-94. 6 Mu Q, Ma Q, Wang Y, Chen Z, Tong X, Chen FF et al. Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population. Ann Hematol 2012; 91: 1065-1072. 7 Burke BA, Carroll M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 2010; 24: 1105-1112. 8 Hehlmann R. How I treat CML blast crisis. Blood 2012; 120: 737-747. 9 Fioretos T, Johansson B. Chronic myeloid anchor leukemia. In: Heim S, Mitelman F (eds). Cancer Cytogenetics. Wiley-Blackwell: Hoboken, NJ, USA, 2009, pp 179-207. 10 Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013 Blood 2013; 122: 872-884. 11 Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukaemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al.(eds). WHO Classifiction of Tumours of Haematopoietic and Lymphoid Tissues.IARC: Lyon, 2008, pp 32-37. 12 Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010; 116: 2673-2681. 13 Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S et al. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica 2010; 95: 1604-1607.